Sort
11,323 grants matching “glioblastoma”
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI
$245,663Ramon Francisco Barajas · Oregon Health & Science University · K08 · FY2021 · CA
Defining the Hypoxic Immunosuppressive Microenvironment as a Biomarker of Therapy Efficacy in Glioblastoma Using Iron Oxide Enhanced FMISO PET/MRI
$245,663Ramon Francisco Barajas · Oregon Health & Science University · K08 · FY2023 · CA
Development of novel synNotch CART cell therapy in adult patients with recurrent EGFRvIII+ glioblastoma
$245,624Hideho Okada · University Of California, San Francisco · U19 · FY2024 · CA
MDA-7/IL-24: Therapy of Malignant Glioma
$245,570Columbia University Health Sciences · P01 · FY2005 · CA
Therapeutic vulnerabilities associated with PTEN missense mutations
$245,438Alain Charest · Beth Israel Deaconess Medical Center · R21 · FY2020 · CA
High-Grade Astrocytoma-specific Molecular Targeting
$245,359Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2012 · CA
High-Grade Astrocytoma-specific Molecular Targeting
$245,359Waldemar Debinski · Wake Forest University Health Sciences · R01 · FY2011 · CA
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
$245,325Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · P50 · FY2014 · CA
The interaction of IDO and Tregs Leads to Immunosuppression in Glioma
$245,193Derek Alan Wainwright · Northwestern University At Chicago · R00 · FY2015 · NS
Highly Multiplexed FISH for In Situ Genomics
$245,121Anthony John Iafrate · Massachusetts General Hospital · R21 · FY2015 · CA
Highly Multiplexed FISH for In Situ Genomics
$245,121Anthony John Iafrate · Massachusetts General Hospital · R21 · FY2017 · CA
Highly Multiplexed FISH for In Situ Genomics
$245,121Anthony John Iafrate · Massachusetts General Hospital · R21 · FY2016 · CA
Targeting the anti-apoptotic protein survivin in glioma
$245,117Roswell Park Cancer Institute Corp · R21 · FY2004 · NS
Targeting Malignant Gliomas with a Novel Inhibitor of the STAT3 Pathway
$245,058Amy Beth Heimberger · University Of Tx Md Anderson Can Ctr · P50 · FY2013 · CA
SYSTEMIC T CELL IMMUNOTHERAPY OF MALIGNANT GLIOMAS
$245,045Cleveland Clinic Foundation · R01 · FY2001 · CA
Radiation effects of MMPs in glioma angiogenesis
$245,009Sanjeeva Mohanam · University Of Illinois At Chicago · R01 · FY2006 · NS
Overcoming Resistance to Anti-VEGF Treatment of Glioblastoma
$244,897Rakesh K. Jain · Massachusetts General Hospital · P01 · FY2014 · CA
Clinical Development of 4-Hydroperoxyifosfamide
$244,853Lee Roy Morgan · Dekk-Tec, Inc. · R44 · FY2007 · CA
Focused Ultrasound and CAR T Cells for Pediatric Brain Malignancies
$244,839Natasha Diba Sheybani · University Of Virginia · R21 · FY2025 · CA
Novel DNA damage response inhibitor and alkylator combinations for GBM
$244,688Ranjit Bindra · Mayo Clinic Rochester · U19 · FY2022 · CA
UNDERSTANDING TRAIL SENSITIVITY IN HUMAN GLIOMA
$244,684Russell O Pieper · University Of California, San Francisco · R01 · FY2006 · CA
Research Training Program in Neuro-Oncology
$244,549Brian Patrick O'Neill · Mayo Clinic Rochester · T32 · FY2020 · CA
Development of an MRI-compatible, High-Frequency Irreversible Electroporation (H-FIRE) System for Non-thermal Ablation of Inoperable Brain Tumors
$244,498Christopher Brian Arena · Voltmed, Inc. · R43 · FY2018 · CA
Overcoming Therapy Resistance in Glioblastoma
$244,389Jann N Sarkaria · Mayo Clinic Rochester · P50 · FY2013 · CA
SPORE: Targeted Therapies for Glioma
$244,260Tracy T Batchelor · Brigham And Women'S Hospital · P50 · FY2021 · CA